Please login to the form below

Not currently logged in
Email:
Password:

eliglustat

This page shows the latest eliglustat news and features for those working in and with pharma, biotech and healthcare.

R&D productivity takes off

R&D productivity takes off

Among these, notable examples include PTC Therapeutics' Translarna (ataluren) - the first medicine approved for the treatment of Duchenne muscular dystrophy (DMD) - and Sanofi/Genzyme's Cerdelga (eliglustat) for Gaucher disease, a

Latest news

  • Genzyme's oral Gaucher drug cleared in Europe Genzyme's oral Gaucher drug cleared in Europe

    Cerdelga (eliglustat) has been cleared by the European Commission (EC) for adults living with Gaucher disease type 1, according to Genzyme's parent Sanofi, which says the drug "will be available

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    The Committee for Medicinal Products for Human Use (CHMP) backed Genzyme's Cerdelga (eliglustat) and Boehringer Ingelheim's Ofev (nintedanib) in its latest round of opinions - which are usually followed by

  • Sanofi plans 18 new product launches by 2020 Sanofi plans 18 new product launches by 2020

    The remainder of its growth portfolio are Cerdelga (eliglustat) for Gaucher disease - the only approved oral, first-line therapy for the rare genetic disease, Lemtrada (alemtuzumab) for multiple sclerosis and sarilumab,

  • FDA gives green light to Genzyme’s oral Gaucher drug FDA gives green light to Genzyme’s oral Gaucher drug

    Genzyme has said it plans to launch Cerdelga (eliglustat), a drug in the glucosylceramide class, within the next month, giving it an oral therapy to suit alongside its widely-used enzyme ... Cerezyme is already the biggest-selling drug for Gaucher

  • Genzyme on track for eliglustat filing in 2013 Genzyme on track for eliglustat filing in 2013

    Genzyme on track for eliglustat filing in 2013. Says oral Gaucher disease drug as effective as its injectable Cerezyme. ... The new data puts eliglustat on track for filing this year with approval potentially coming in 2014.

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics